Dramatic results seen in phase III front-line multiple myeloma trials of bortezomib-based therapy

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2008年 / 22卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [21] Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Zhang, Shijia
    Kulkarni, Amit A.
    Xu, Beibei
    Chu, Haitao
    Kourelis, Taxiarchis
    Go, Ronald S.
    Wang, Michael L.
    Bachanova, Veronika
    Wang, Yucai
    BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [22] Bortezomib as front line therapy in advanced multiple myeloma: A single center experience
    Mazza, P.
    Specchia, M. R.
    Casulli, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 234 - 234
  • [23] Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Feng, Lei
    Berkova, Zuzana
    Hildebrandt, Michelle
    Orlowski, Robert Z.
    LANCET HAEMATOLOGY, 2018, 5 (12): : E628 - E640
  • [24] Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma
    Lok, Anne
    Mocquard, Julie
    Bourcier, Jessie
    Redelsperger, Laurence
    Bonnet, Antoine
    Chauvin, Cecile
    Thomare, Patrick
    Mahe, Beatrice
    Touzeau, Cyrille
    Moreau, Philippe
    HAEMATOLOGICA, 2014, 99 (03) : E33 - E34
  • [25] Phase III results of bortezomib use in previously untreated multiple myeloma
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (01) : 14 - 14
  • [26] Bortezomib-Based Therapy Following Prior Lenalidomide plus Dexamethasone in Relapsed Multiple Myeloma
    Trieu, Y.
    Xu, W.
    Masih-Khan, E.
    Dean, S.
    Trudel, S.
    Kukreti, V.
    Anglin, P.
    Chen, C.
    Mikhael, J.
    Reece, D.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S53 - S54
  • [27] A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
    Wei, Daolin
    Tong, Yin
    Bai, Haitao
    Cai, Qi
    Gao, Yanrong
    Wang, Chun
    ONCOTARGET, 2016, 7 (43) : 70168 - 70174
  • [28] Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
    Liu, Xiaoping
    He, Colin K.
    Meng, Xiangyu
    He, Li
    Li, Kaili
    Liang, Qing
    Shao, Liang
    Liu, Shangqin
    ONCOTARGETS AND THERAPY, 2015, 8 : 1459 - 1469
  • [29] AFRICAN-AMERICANS WITH MULTIPLE MYELOMA RECEIVE SHORTER DURATIONS OF FRONT-LINE THERAPY
    Fiala, Mark A.
    Wildes, Tanya M.
    Vij, Ravi
    ANTICANCER RESEARCH, 2019, 39 (10) : 5836 - 5837
  • [30] The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study
    Baltathakis, Ioannis
    Terpos, Evangelos
    Delimpasi, Sosana
    Liapis, Konstantinos
    Panitsas, Fotios
    Kastritis, Efstathios
    Christoforidou, Anna
    Pouli, Anastasia
    Tsatalas, Konstantinos
    Dimopoulos, Meletios A.
    Harhalakis, Nikolaos
    BLOOD, 2010, 116 (21) : 1258 - 1259
12345